Ixekizumab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ixekizumab: From Psoriatic Arthritis / Axial Spondyloarthritis to Rheumatoid Vasculitis
One-Sentence Summary
Ixekizumab is an IL-17A-targeting monoclonal antibody; the clinical trial and literature evidence embedded in this pack show it is an established treatment for psoriatic arthritis and axial spondyloarthritis (Taltz), though no TFDA-approved indication text is available because the drug is not yet marketed in Taiwan. The TxGNN model’s top-ranked prediction is Rheumatoid Vasculitis, but this is currently supported by only 1 clinical trial (indirect relevance, not yet recruiting) and 0 publications — evidence is minimal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from Taiwan regulatory data (未上市). Based on trial/literature evidence in this pack, ixekizumab (IL-17A inhibitor) is established for psoriatic arthritis and axial spondyloarthritis |
| Predicted New Indication | Rheumatoid Vasculitis |
| TxGNN Prediction Score | 97.53% |
| Evidence Level | L5 |
| Taiwan Market Status | 未上市 (Not Marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (drug.original_moa = Data Gap). Based on evidence embedded elsewhere in this pack, ixekizumab is a high-affinity monoclonal antibody that selectively neutralizes interleukin-17A (IL-17A), a cytokine central to the pathogenesis of psoriasis, psoriatic arthritis, and axial spondyloarthritis — indications with extensive Phase 3 trial support (see the “vertebral disease” / “inflammatory spondylopathy” evidence below).
For the top-ranked candidate, rheumatoid vasculitis, the evidence pack’s own rationale states that “IL-17A’s role in rheumatoid vasculitis lacks clear literature support; existing RV pathology centers on immune-complex deposition and TNF/B-cell pathways, and the causal link to IL-17A inhibition is weak — this is a KG score-driven hypothesis” rather than an established mechanistic connection. Only one indirectly-relevant, not-yet-recruiting Phase 2 trial (NCT07138898, on perioperative immunosuppressant management in shoulder arthroplasty, grade C relevance) exists, and no supporting literature was found.
Data quality caveat: Several other high-scoring candidates in this pack (e.g., “inflammatory spondylopathy” rank 6, “vertebral disease” rank 9) show strong L1/Phase-3-level evidence, but their own rationale text flags that these are very likely already-approved indications (axSpA/PsA) surfacing as “novel predictions” only because drug.original_indications is empty in this dataset — not genuine repurposing opportunities. This should be corrected at the data source before further use.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT07138898 | Phase 2 | Not Yet Recruiting | 80 | Assesses rheumatologic flares, pain/functional outcomes, and surgical complications in rheumatology patients undergoing shoulder arthroplasty, comparing preoperative immunosuppressant-holding strategies; not a direct ixekizumab-in-RV efficacy trial (relevance grade C, indirect) |
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Ixekizumab currently has no TFDA drug license on record (0 NDAs; market status: 未上市/Not Marketed).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for ixekizumab in rheumatoid vasculitis is at the model-prediction-only stage (L5) — a single indirect, not-yet-recruiting trial and no supporting literature. The mechanistic rationale itself is described as weak and KG-score-driven rather than biologically established.
To proceed, the following is needed:
- TFDA package insert / warnings and contraindications (currently blocking — DG001)
- DrugBank-confirmed mechanism of action (currently High-severity gap — DG002)
- A confirmed, TFDA-independent record of ixekizumab’s actual approved indications (drug.original_indications is empty, which is also causing already-approved indications like axSpA/PsA to misleadingly appear as “predictions”)
- Mechanistic or preclinical evidence specifically linking IL-17A inhibition to rheumatoid vasculitis pathology
- At minimum one enrolling/completed clinical trial directly testing ixekizumab in rheumatoid vasculitis before advancing past Hold
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.